eprintid: 10064190
rev_number: 17
eprint_status: archive
userid: 608
dir: disk0/10/06/41/90
datestamp: 2018-12-17 08:30:34
lastmod: 2021-10-15 22:29:52
status_changed: 2018-12-17 08:30:34
type: article
metadata_visibility: show
creators_name: Öhrfelt, A
creators_name: Brinkmalm, A
creators_name: Dumurgier, J
creators_name: Zetterberg, H
creators_name: Bouaziz-Amar, E
creators_name: Hugon, J
creators_name: Paquet, C
creators_name: Blennow, K
title: A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer's disease
ispublished: inpress
divisions: UCL
divisions: B02
divisions: C07
divisions: D07
divisions: F86
keywords: Alzheimer’s disease, Biomarker, Cerebrospinal fluid, ELISA, Mild cognitive impairment, SNAP-25
note: © 2018 The Authors.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
abstract: Synaptic degeneration is central in Alzheimer's disease (AD) pathogenesis and biomarkers to monitor this pathophysiology in living patients are warranted. We developed a novel sandwich enzyme-linked immunosorbent assay (ELISA) for the measurement of the pre-synaptic protein SNAP-25 in cerebrospinal fluid (CSF) and evaluated it as a biomarker for AD. CSF samples included a pilot study consisting of AD (N=26) and controls (N=26), and two independent clinical cohorts of AD patients and controls. Cohort I included CSF samples from patients with dementia due to AD (N=17), patients with mild cognitive impairment (MCI) due to AD (N=5) and controls (N=17), and cohort II CSF samples from patients with dementia due to AD (N=24), patients with MCI due to AD (N=18) and controls (N=36). CSF levels of SNAP-25 were significantly increased in patients with AD compared with controls (P≤0.00001). In both clinical cohorts, CSF levels of SNAP-25 were significantly increased in patients with MCI due to AD (P<0.0001). SNAP-25 could differentiate dementia due to AD (N=41) from controls (N=52) and MCI due to AD (N=23) from controls (N=52) with areas under the curve of 0.967 (P<0.0001) and 0.948 (P<0.0001), respectively. CSF SNAP-25 is a promising AD biomarker that differentiates AD patients in different clinical stages of the disease from controls with excellent diagnostic accuracy. Future studies should address the specificity of the CSF SNAP-25 against common differential diagnoses to AD, as well as how the biomarker changes in response to treatment with disease-modifying drug candidates.
date: 2018
date_type: published
official_url: https://doi.org/10.1016/j.neuroscience.2018.11.038
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
article_type_text: Journal Article
verified: verified_manual
elements_id: 1608823
doi: 10.1016/j.neuroscience.2018.11.038
pii: S0306-4522(18)30780-2
lyricists_name: Zetterberg, Henrik
lyricists_id: HZETT94
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Neuroscience
event_location: United States
issn: 1873-7544
citation:        Öhrfelt, A;    Brinkmalm, A;    Dumurgier, J;    Zetterberg, H;    Bouaziz-Amar, E;    Hugon, J;    Paquet, C;           Öhrfelt, A;  Brinkmalm, A;  Dumurgier, J;  Zetterberg, H;  Bouaziz-Amar, E;  Hugon, J;  Paquet, C;  Blennow, K;   - view fewer <#>    (2018)    A novel ELISA for the measurement of cerebrospinal fluid SNAP-25 in patients with Alzheimer's disease.                   Neuroscience        10.1016/j.neuroscience.2018.11.038 <https://doi.org/10.1016/j.neuroscience.2018.11.038>.    (In press).    Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10064190/1/1-s2.0-S0306452218307802-main.pdf